24/7 Market News Snapshot 27 March, 2025 – CERo Therapeutics Holdings, Inc. Common Stock (NASDAQ:CERO)

March 27, 2025

DENVER, Colo., 27 March, 2025 (247marketnews.com) – (Nasdaq:CERO) are discussed in this article.
CERo Therapeutics Holdings, Inc. (Nasdaq:CERO) is witnessing a notable surge in its stock performance, currently trading at $0.865 in pre-market sessions, reflecting a 2.32% increase from the previous close of $0.845. The trading volume of 2.97 million shares indicates robust investor interest, potentially signaling momentum driven by recent corporate developments and the associated positive market sentiment. Investors are encouraged to monitor key resistance levels and overall market conditions to evaluate the sustainability of this upward trend.

In a significant announcement, CERo Therapeutics has confirmed the acceptance of an abstract for presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) annual conference, scheduled for May 30 to June 5. This strategic achievement aligns with the Company’s advancements toward initiating clinical trials for its leading product candidate, CER-1236. Following a positive review from the U.S. Food and Drug Administration (FDA) on its amendment related to Chemistry, Manufacturing and Controls (CMC), the Company is set for an expedited manufacturing timeline, positioning it to commence patient dosing in the first half of 2025.

Chris Ehrlich, CEO of CERo Therapeutics, highlighted the significance of this FDA milestone, stating, “This is a key completion as we ramp up for initiating our clinical trial of CER-1236. Our dedicated team, alongside top-notch consultants and partners, has worked diligently to ensure that we avoid delays often associated with initiating trials.”

The upcoming clinical trial represents a first-in-human, multi-center, open-label Phase 1/1b study focused on assessing the safety and initial efficacy of CER-1236 in patients with relapsed/refractory measurable residual disease positive acute myeloid leukemia. As CERo Therapeutics advances its innovative Chimeric Engulfment Receptor T cell (CER-T) technology, further updates regarding the ASCO abstract presentation and the overall program developments are anticipated shortly.

Related news for (CERO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.